These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35211559)

  • 1. Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
    Yang J; Wang Y; Tong XM
    World J Clin Cases; 2022 Feb; 10(4):1263-1277. PubMed ID: 35211559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
    Fischer M; Amos S; Levy L; Pollack R
    Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer.
    Sothornwit J; Phunmanee A; Pongchaiyakul C
    Front Endocrinol (Lausanne); 2019; 10():352. PubMed ID: 31244772
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review.
    Huang X; Yang M; Wang L; Li L; Zhong X
    Medicine (Baltimore); 2021 May; 100(19):e25795. PubMed ID: 34106616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
    Patel S; Chin V; Greenfield JR
    Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
    Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
    Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
    Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
    Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV.
    Hughes MS; Pietropaolo M; Vasudevan MM; Marcelli M; Nguyen H
    J Endocr Soc; 2020 Dec; 4(12):bvaa150. PubMed ID: 33225197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.
    Wen YP; Xiao HW; Yin JH; Guo HR; Shan MJ; Shen LP; Liu LS
    Medicine (Baltimore); 2022 Dec; 101(48):e32076. PubMed ID: 36482651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors.
    Chen X; Ye M; Ai R; Shan C; Lai M; Hong W; Yang Y; Wang H; Li J; Zhen J; Zhou J; Hu Q; Li S; Rossi A; Hida T; Rosell R; Zhong S; Cai L
    Transl Cancer Res; 2024 Feb; 13(2):1196-1207. PubMed ID: 38482411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review.
    Zhou S; Zhang Z; Feng X; Zhao C; Jiang L
    Front Pharmacol; 2023; 14():1276788. PubMed ID: 38161699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
    Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
    Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
    Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
    Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.